Switch theme
Sign up to access all valuation multiples
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, Asia, and the Rest of the World. The firm's activity is split into three strategic operating units, Capital equipment; Lease of equipment, and Distribution and sales of third-party products.
1984
152
LTM Revenue $50.1M
LTM EBITDA $14.7M
$249M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medistim has a last 12-month revenue of $50.1M and a last 12-month EBITDA of $14.7M.
In the most recent fiscal year, Medistim achieved revenue of $46.7M and an EBITDA of $14.3M.
Medistim expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medistim valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $43.6M | $46.7M | $49.6M | $50.1M | XXX |
| Gross Profit | $28.7M | $34.0M | $36.6M | XXX | XXX |
| Gross Margin | 66% | 73% | 74% | XXX | XXX |
| EBITDA | $15.2M | $14.3M | $14.6M | $14.7M | XXX |
| EBITDA Margin | 35% | 31% | 29% | 29% | XXX |
| Net Profit | $8.1M | $10.2M | $9.3M | XXX | XXX |
| Net Margin | 19% | 22% | 19% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Medistim's stock price is NOK 158 (or $14).
Medistim has current market cap of NOK 2.9B (or $259M), and EV of NOK 2.8B (or $249M).
See Medistim trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $249M | $259M | XXX | XXX | XXX | XXX | $0.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Medistim has market cap of $259M and EV of $249M.
Medistim's trades at 5.0x LTM EV/Revenue multiple, and 16.9x LTM EBITDA.
Analysts estimate Medistim's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medistim and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $249M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | 17.1x | XXX | XXX | XXX |
| P/E | 26.4x | XXX | XXX | XXX |
| P/E/Growth | 13.0x | XXX | XXX | XXX |
| EV/FCF | 32.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMedistim's NTM/LTM revenue growth is 5%
Medistim's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Medistim's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medistim's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medistim and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 35% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 53% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Electromed | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medistim acquired XXX companies to date.
Last acquisition by Medistim was XXXXXXXX, XXXXX XXXXX XXXXXX . Medistim acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Medistim founded? | Medistim was founded in 1984. |
| Where is Medistim headquartered? | Medistim is headquartered in Norway. |
| How many employees does Medistim have? | As of today, Medistim has 152 employees. |
| Who is the CEO of Medistim? | Medistim's CEO is Ms. Kari Eian Krogstad. |
| Is Medistim publicy listed? | Yes, Medistim is a public company listed on OSL. |
| What is the stock symbol of Medistim? | Medistim trades under MEDI ticker. |
| When did Medistim go public? | Medistim went public in 2004. |
| Who are competitors of Medistim? | Similar companies to Medistim include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem. |
| What is the current market cap of Medistim? | Medistim's current market cap is $259M |
| What is the current revenue of Medistim? | Medistim's last 12-month revenue is $50.1M. |
| What is the current EBITDA of Medistim? | Medistim's last 12-month EBITDA is $14.7M. |
| What is the current EV/Revenue multiple of Medistim? | Current revenue multiple of Medistim is 5.0x. |
| What is the current EV/EBITDA multiple of Medistim? | Current EBITDA multiple of Medistim is 16.9x. |
| What is the current revenue growth of Medistim? | Medistim revenue growth between 2023 and 2024 was 6%. |
| Is Medistim profitable? | Yes, Medistim is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
